GE Healthcare, the healthcare business of General Electric and M+W Group, a leading global engineering, construction and project management company, announced that the companies have formed a strategic alliance aimed at overcoming the lack of key biopharmaceuticals, especially in emerging nations.
The alliance, which will combine GE Healthcare’s expertise in technologies for biopharmaceutical manufacture with M+W Group’s global capabilities in bio-engineering and construction, will assist countries worldwide to become self-sufficient in the manufacture of vital biopharmaceuticals such as vaccines, insulin and biosimilars.
Together, the companies will offer governments and pharmaceutical companies an integrated, cost-competitive “turn-key” approach for the construction of biopharmaceutical manufacturing plants, to help meet the rapidly increasing worldwide demand for these potentially life-saving treatments. The alliance between the two companies aligns with GE’s healthymagination initiative, which focuses on reducing cost, increasing access and improving quality in healthcare.
Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences said “We’re delighted to form this alliance with M+W Group, who share our vision of bringing affordable and flexible manufacturing capabilities to countries worldwide, especially the emerging nations. This is a big step forward in bringing better, more affordable healthcare to more people. M+W are one of the foremost global engineering companies in bioengineering. By working together to bring an integrated offering – from financing and construction of the plant, right through to training of the operational staff – we can make it much easier for governments to set up their own facilities.”
Editor’s comment: This is an another strategic alliance in biosimilars area. We are definitely sure that more will come in the near future…
Source: GE Healthcare press release